The Motley Fool

3 More FTSE 100 Shares Paying 5%+ Dividends: HSBC Holdings plc, BP plc And AstraZeneca plc


By market capitalisation, Shell is the only FTSE 100 company larger than HSBC. While rivals Royal Bank of Scotland and Lloyds Banking may get all the press attention, HSBC (LSE: HSBA)(NYSE: HBC.US) is the the largest by far. By market capitalisation, HSBC is more than twice the size of both.

HSBC’s global footprint makes it unique among UK banks. This diversity gives the bank further strength.

Sign up for FREE issues of The Motley Fool Collective. Do you want straightforward views on what’s happening with the stock market, direct to your inbox? Help yourself with our FREE email newsletter designed to help you protect and grow your portfolio. Click here to get started now — it’s FREE!

Although the forecast yield for 2013 comes in at 4.7%, a big increase is forecast next year. This would push the yield to 5.2%, well ahead of what can be achieved on deposit with the bank itself.

According to the consensus forecast for the year, HSBC shares trade on a P/E of 11.6, falling to 10.6 times next year’s expected numbers.


BP (LSE: BP)(NYSE: BP.US) shareholders are still waiting for a line to be drawn under the company’s Gulf of Mexico spill. Although the current price in the market may look cheap, there remains the possibility of further large fines.

Either way, I still expect BP to reward its shareholders with big dividends.

This year, BP is expected to announce a total of $0.37 of dividends per share. At today’s share price, that’s a yield of 5.2%. An 8% dividend rise is expected next year, pushing the yield to 5.6%.

As for earnings, BP is forecast to make earnings per share (EPS) of $0.78 this year and $0.90 by 2014. That’s a P/E for this year of 9.0, falling to 7.8 for 2014.


Pharmaceutical firms like AstraZeneca (LSE: AZN) have a strong relationship with their customers. For as long at their products are protected by patents, sales are almost guaranteed. However, AstraZeneca shares have struggled in recent years, over concerns that its portfolio of forthcoming patent-protected drugs is looking thin.

This has created an opportunity for income investors. AstraZeneca has maintained its dividend in the face share price falls. This has pushed the yield on the shares to 5.5%.

Although earnings are expected to fall this year and next, the dividend looks safe for awhile yet. Management may cut the payout to fund a big acquisition at some point in the future. All things considered, AstraZeneca looks a decent way to get pharma representation in an income portfolio.

Our analysts believe that they have identified an even better dividend prospect in the FTSE 100 than any of these companies. Their research is free to read in the report "The Motley Fool's Top Income Share For 2013". To receive this analysis immediately, click here.

> David owns shares in Royal Bank of Scotland but none of the other companies mentioned.